DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Joubert syndrome 20 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJoubert syndrome 20 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for joubert syndrome 20 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Joubert syndrome is an autosomal recessive congenital disorder with characteristic clinical features including hypotonia, ataxia, developmental delay, and a distinctive cerebellar and brainstem malformation called the molar tooth sign on cranial MRI. Other variable features include retinal dystrophy, cystic kidney disease, and liver fibrosis. Endocrine manifestations may arise from hypothalamic-pituitary dysfunction, leading to growth hormone deficiency, hypothyroidism, adrenal insufficiency, and hypogonadism. Treatment is symptomatic and supportive; infant stimulation and physical, occupational, and speech therapy may benefit some patients, and infants with abnormal breathing patterns should be monitored.
In a case series from 2002, 4 of 11 patients (36.36%) with Joubert syndrome presented a favourable evolution. Their ages ranged from 25 months to 12 years. Comprehensive language corresponded to their ages in 3 patients; 2 patients began talking at 19 and 20 months respectively. Three children exhibited normal language, while 1 only communicated by gestures at the last clinical study. All 4 children walked without help. Mental level was calculated by the Raven scale in 2 cases, showing a borderline intellectual quotient. Both patients were self-sufficient in daily cleanliness and feeding, and 1 patient could read, write, and make mathematical calculations. The authors concluded that Joubert syndrome is heterogeneous in clinic, genetics, and evolution, and that an attentive neuropsychological evaluation is necessary before giving a prognosis.
No drug treatment for Joubert syndrome itself is described in these abstracts. The 2011 case report states only that treatment is symptomatic and supportive. The 2023 literature review discusses screening, diagnosis, and management of endocrine manifestations but does not report any trial of a specific drug. The 2022 case report emphasises early diagnosis and appropriate rehabilitation but offers no pharmacological intervention.
What is still missing is any clinical trial of a drug intended to modify the underlying disease course, any evidence of effective pharmacological therapy, and any systematic patient stratification that might identify subgroups more likely to respond to a given treatment. Funding for such trials and for the development of outcome measures suitable for this rare, heterogeneous condition also remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Nepal Paediatric Society · 2011 · 3 citations · open access
Joubert's Syndrome: A Case Report
AbstractJoubert's syndrome is an autosomal recessive congenital disorder having characteristic clinical features like hypotonia, ataxia, developmental delay and many neurological problems. Other variable features include retinal dystrophy, cystic kidney disease liver fibrosis etc. Treatment for Joubert syndrome is symptomatic and supportive. Infant stimulation and physical, occupational, and speech therapy may benefit some patients. Infants with abnormal breathing patterns should be monitored. Key words: Joubert's syndrome; molar tooth sign; cerebellar peduncles; vermis hypoplasia. DOI: 10.3126/jnps.v31i2.3908 J Nep Paedtr Soc 2010;31(2):141-142
Síndrome de Joubert. Presentación de cuatro casos con evolución favorable
AbstractOBJECTIVES: To present 4 patients with Joubert syndrome who had a favourable evolution as well as to show that many cases have better prognosis than it is usually though. CASE REPORT: Anamnesis, image and psychological studies of 4 children with Joubert syndrome, who had been seen in the Pediatric Neurology Service of the University Hospital La Paz of Madrid. RESULTS: Four of our 11 patients with Joubert syndrome (36.36%) presented a favourable evolution. Their age ranged between 25 months old and 12 years old. The comprehensive language corresponded to their ages in 3 patients. Two patients began to talk at 19 and 20 months respectively. Three children exhibited a normal language and 1 only communicated by gestures at the time of the last clinical study. All the four children walked without help. The mental level was calculated by the Raven scale in 2 cases and they showed a borderline intellectual quotient (IQ). Both patients were self sufficient in their daily cleanliness and feeding. A patient was able to read, to write and to make mathematical calculi. CONCLUSIONS: The Joubert syndrome is a heterogeneous disease from the clinic and genetics points of view, as well as in the evolution. Because of that, an attentive neuropsychological evaluation is necessary before giving the prognosis of the children.
AIMS Medical Science · 2023 · 0 citations · open access
Endocrine manifestations in Joubert syndrome—literature review
Abstract<abstract> <p>Joubert syndrome (JS) is a heterogeneously inherited, rare, autosomal recessive disorder characterised by neonatal breathing dysregulation, developmental delay, hypotonia, abnormal eye movements and a distinctive cerebellar and brainstem malformation called the molar tooth sign (MTS). Patients with JS may develop hypothalamic-pituitary dysfunction, leading to growth hormone deficiency, hypothyroidism, adrenal insufficiency and hypogonadism. This review summarizes the screening, diagnosis, and management of these conditions in JS.</p> </abstract>
Turkish Journal of Pediatric Disease · 2022 · 0 citations · open access
Nadir Bir Siliopati: Joubert Sendromu
AbstractJoubert syndrome is a rare autosomal recessive ciliopathy characterized by abnormal breathing patterns, hypotonia, ataxia, cerebellar vermis hypoplasia, developmental delay, ocular abnormalities, renal cysts and hepatic fibrosis. Molar tooth appearance on cranial magnetic resonance imaging (MRI) is an important finding for the diagnosis of Joubert syndrome. Awareness of the characteristic clinical and radiological findings of the syndrome will allow early diagnosis, appropriate counseling and proper rehabilitation. A patient who admitted to our hospital with hypotonia and abnormal eye movements and was diagnosed with Joubert syndrome is presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
